News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Integrated DNA Technologies Reduces Undesirable Effects Of RNAi Protocols


3/11/2014 10:35:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CORALVILLE, IA – 11 March 2014 – Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, will present two keynote addresses at the upcoming RNAi International Conference and Exhibition and its co-hosted symposium, Aptamers. Providing a forum for the discussion of long and short non-coding RNAs, their role in gene regulation, functional studies, RNA biomarkers and therapeutic application, IDT CSO Dr Mark Behlke will share IDT’s expertise within the advancing field of RNAi.

Forming part of the Aptamers track (24-25 March), Dr Behlke will discuss how aptamers can be employed as a targeting ligand to deliver therapeutic cargo to specific cell types. Such cargo can be attached following aptamer synthesis using reactive chemistries or through hybridization to a ‘stick’ domain. Attachment using the ‘stick’ domain is highly flexible and allows the use of a broad variety of cargo types. However the addition of the ‘anti-stick’ sequence to facilitate release of the cargo can prove problematic, with reduced siRNA potency often experienced. Design considerations to minimize these undesirable effects will therefore be explored.

Off-target effects are a chronic problem for studies employing RNAi, since the seed region directs suppression of unknown targets via miRNA. Bioinformatic methods have been developed, however a 7mer seed region has thousands of possible binding sites and it is extremely difficult to predict which of these are significant. Chemical methods can reduce the incidence of these effects, but will cause a reduction in the potency of the siRNA. During RNAi (25-27 March), Dr Behlke will discuss Unlocked Nucleic Acids (UNAs), which have previously been proven useful in the reduction of off-target effects while retaining potency. This presentation will cover the use of UNAs in Dicer-substrate siRNAs (DisRNA), comparing position-specific UNA effects on seed region off-target effects and potency.

For more information please visit the Aptamers or RNAi conferences in Oxford, UK, or www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.

About IDT

Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; Leuven, Belgium; and Singapore. For more information visit www.idtdna.com.

Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)
productinfo@idtdna.com
www.idtdna.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES